Francois Dreyfus
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Journal: Haematologica
Published: June 27, 2018
Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload.
Journal: European journal of haematology
Published: April 19, 2018
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.
Journal: Leukemia research
Published: April 09, 2018
Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.
Journal: Blood cancer journal
Published: June 03, 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 29, 2017
Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 28, 2017
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.
Journal: Blood
Published: August 19, 2016
Time-dependent changes in mortality and transformation risk in MDS.
Journal: Blood
Published: February 12, 2016
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.
Journal: British journal of haematology
Published: January 17, 2016
A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
Journal: Haematologica
Published: December 21, 2015
Last Updated: 09/26/2026